Becton Dickinson and Co (BDX) was Downgraded by Citigroup to ” Sell”. Earlier the firm had a rating of “Neutral ” on the company shares. Citigroup advised their investors in a research report released on Sep 23, 2016.
On the company’s financial health, Becton Dickinson and Co reported $2.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.15 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.20. The company had revenue of $3198.00 million for the quarter, compared to analysts expectations of $3202.11 million. The company’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS.
Becton Dickinson and Co opened for trading at $180 and hit $181.755 on the upside on Thursday, eventually ending the session at $181.55, with a gain of 1.21% or 2.17 points. The heightened volatility saw the trading volume jump to 6,82,201 shares. Company has a market cap of $38,657 M.
In a different news, on Sep 7, 2016, Linda M Tharby (Executive Vice President) sold 11,704 shares at $177.34 per share price. According to the SEC, on Aug 12, 2016, Gary M Cohen (Executive Vice President) sold 29,367 shares at $176.81 per share price. On Jun 14, 2016, John E Gallagher (VP, Corp Finance and Treasurer) sold 1,931 shares at $169.87 per share price, according to the Form-4 filing with the securities and exchange commission.
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.